These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33764774)

  • 1. Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery.
    Pei J; Wang G; Feng L; Zhang J; Jiang T; Sun Q; Ouyang L
    J Med Chem; 2021 Apr; 64(7):3493-3507. PubMed ID: 33764774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications].
    Reboud-Ravaux M
    Biol Aujourdhui; 2024; 218(1-2):41-54. PubMed ID: 39007776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LYST affects lysosome size and quantity, but not trafficking or degradation through autophagy or endocytosis.
    Holland P; Torgersen ML; Sandvig K; Simonsen A
    Traffic; 2014 Dec; 15(12):1390-405. PubMed ID: 25216107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy.
    Wang J; Wang Y; Yang F; Luo Q; Hou Z; Xing Y; Lu F; Li Z; Yin F
    ACS Chem Biol; 2024 May; 19(5):1161-1168. PubMed ID: 38662199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond.
    Zhong Y; Chi F; Wu H; Liu Y; Xie Z; Huang W; Shi W; Qian H
    Eur J Med Chem; 2022 Mar; 231():114142. PubMed ID: 35092900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins.
    Chen S; Wang W; Chen Z; Li R; Wu Z; Dong G; Sheng C
    J Med Chem; 2024 Sep; 67(17):15807-15815. PubMed ID: 39146536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosome-targeting chimaeras for degradation of extracellular proteins.
    Banik SM; Pedram K; Wisnovsky S; Ahn G; Riley NM; Bertozzi CR
    Nature; 2020 Aug; 584(7820):291-297. PubMed ID: 32728216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
    Sha Z; Zhao J; Goldberg AL
    Methods Mol Biol; 2018; 1844():261-276. PubMed ID: 30242715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadmium-induced cytotoxicity in mouse liver cells is associated with the disruption of autophagic flux via inhibiting the fusion of autophagosomes and lysosomes.
    Zou H; Wang T; Yuan J; Sun J; Yuan Y; Gu J; Liu X; Bian J; Liu Z
    Toxicol Lett; 2020 Mar; 321():32-43. PubMed ID: 31862506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
    Liang Y; Nandakumar KS; Cheng K
    Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras.
    Ahn G; Riley NM; Kamber RA; Wisnovsky S; Moncayo von Hase S; Bassik MC; Banik SM; Bertozzi CR
    Science; 2023 Oct; 382(6668):eadf6249. PubMed ID: 37856615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosome and related protein degradation technologies.
    Zheng H; Li G; Min J; Xu X; Huang W
    Drug Discov Today; 2023 Nov; 28(11):103767. PubMed ID: 37708931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
    Tomaselli D; Mautone N; Mai A; Rotili D
    Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifaceted targeted protein degradation systems for different cellular compartments.
    Zorca CE; Fallahi A; Luo S; Eldeeb MA
    Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 20. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.